Thermo Fisher Scientific SARM Polyclonal Antibody

Applications and Tested Dilution

Product Specifications

Product Specific Information

Specific for endogenous levels of the ~79 kDa SARM1 protein.

Target Information

NAD(+) hydrolase, which plays a key role in axonal degeneration following injury by regulating NAD(+) metabolism (PubMed:25908823, PubMed:27671644, PubMed:28334607).
Acts as a negative regulator of MYD88- and TRIF-dependent toll-like receptor signaling pathway by promoting Wallerian degeneration, an injury-induced form of programmed subcellular death involving degeneration of an axon distal to the injury site (PubMed:15123841, PubMed:16964262, PubMed:20306472, PubMed:25908823).
Wallerian degeneration is triggered by NAD(+) depletion: upon injury, SARM1 is activated and catalyzes cleavage of NAD(+) into ADP-D-ribose (ADPR), cyclic ADPR (cADPR), and nicotinamide; NAD(+) cleavage promotes cytoskeletal degradation and axon destruction (PubMed:25908823, PubMed:28334607, PubMed:30333228, PubMed:31128467, PubMed:31439793, PubMed:31439792).
Also able to hydrolyze NADP(+), but not other NAD(+)-related molecules (PubMed:29395922).
Can activate neuronal cell death in response to stress (PubMed:20306472).
Regulates dendritic arborization through the MAPK4-JNK pathway.
Involved in innate immune response: inhibits both TICAM1/TRIF- and MYD88-dependent activation of JUN/AP-1, TRIF-dependent activation of NF-kappa-B and IRF3, and the phosphorylation of MAPK14/p38 (PubMed:16964262).
[UniProt]

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.